American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

被引：346

作者：

Ellis, Lee M. ^{[1
]}

Bernstein, David S. ^{[2
]}

Voest, Emile E. ^{[3
]}

Berlin, Jordan D. ^{[4
]}

Sargent, Daniel ^{[5
]}

Cortazar, Patricia ^{[6
]}

Garrett-Mayer, Elizabeth ^{[7
]}

Herbst, Roy S. ^{[8
]}

Lilenbaum, Rogerio C. ^{[8
]}

Sima, Camelia ^{[9
]}

Venook, Alan P. ^{[10
]}

Gonen, Mithat ^{[9
]}

Schilsky, Richard L. ^{[2
]}

Meropol, Neal J. ^{[11
]}

Schnipper, Lowell E. ^{[12
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77230 USA

[2] Amer Soc Clin Oncol, Alexandria, VA USA

[3] Univ Med Ctr Utrecht, Utrecht, Netherlands

[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] Mayo Clin, Rochester, MN USA

[6] US FDA, Silver Spring, MD USA

[7] Med Univ S Carolina, Charleston, SC 29425 USA

[8] Yale Canc Ctr, New Haven, CT USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[10] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[11] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA

[12] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 12期

关键词：

METASTATIC BREAST-CANCER; CELL LUNG-CANCER; PANCREATIC-CANCER; HEDGEHOG PATHWAY; APPROVAL; INHIBITION; SURVIVAL; CHEMOTHERAPY; TRASTUZUMAB; GEMCITABINE;

D O I：

10.1200/JCO.2013.53.8009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

[No abstract available]

引用

页码：1277 / +

页数：7

共 27 条

[1]

[Anonymous], FDA APPR CRIZ

[2]

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer [J].

Blumenthal, Gideon M. ;

Scher, Nancy S. ;

Cortazar, Patricia ;

Chattopadhyay, Somesh ;

Tang, Shenghui ;

Song, Pengfei ;

Liu, Qi ;

Ringgold, Kimberly ;

Pilaro, Anne M. ;

Tilley, Amy ;

King, Kathryn E. ;

Graham, Laurie ;

Rellahan, Barbara L. ;

Weinberg, Wendy C. ;

Chi, Bo ;

Thomas, Colleen ;

Hughes, Patricia ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2013, 19 (18) :4911-4916

[3]

US Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia [J].

Casak, Sandra J. ;

Lemery, Steven J. ;

Shen, Yuan Li ;

Rothmann, Mark D. ;

Khandelwal, Aakanksha ;

Zhao, Hong ;

Davis, Gina ;

Jarral, Vaishali ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2011, 16 (01) :97-104

[4]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[5]

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[6]

US Food and Drug Administration Approval Overview in Metastatic Breast Cancer [J].

Cortazar, Patricia ;

Justice, Robert ;

Johnson, John ;

Sridhara, Rajeshwari ;

Keegan, Patricia ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1705-1711

[7]

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis [J].

Deisseroth, Albert ;

Kaminskas, Edvardas ;

Grillo, Joseph ;

Chen, Wei ;

Saber, Haleh ;

Lu, Hong L. ;

Rothmann, Mark D. ;

Brar, Satjit ;

Wang, Jian ;

Garnett, Christine ;

Bullock, Julie ;

Burke, Laurie B. ;

Rahman, Atiqur ;

Sridhara, Rajeshwari ;

Farrell, Ann ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2012, 18 (12) :3212-3217

[8]

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].

Diaz, Luis A., Jr. ;

Williams, Richard T. ;

Wu, Jian ;

Kinde, Isaac ;

Hecht, J. Randolph ;

Berlin, Jordan ;

Allen, Benjamin ;

Bozic, Ivana ;

Reiter, Johannes G. ;

Nowak, Martin A. ;

Kinzler, Kenneth W. ;

Oliner, Kelly S. ;

Vogelstein, Bert .

NATURE, 2012, 486 (7404) :537-540

[9]

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

[10]

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J].

Grothey, Axel ;

Van Cutsem, Eric ;

Sobrero, Alberto ;

Siena, Salvatore ;

Falcone, Alfredo ;

Ychou, Marc ;

Humblet, Yves ;

Bouche, Olivier ;

Mineur, Laurent ;

Barone, Carlo ;

Adenis, Antoine ;

Tabernero, Josep ;

Yoshino, Takayuki ;

Lenz, Heinz-Josef ;

Goldberg, Richard M. ;

Sargent, Daniel J. ;

Cihon, Frank ;

Cupit, Lisa ;

Wagner, Andrea ;

Laurent, Dirk .

LANCET, 2013, 381 (9863) :303-312

← 1 2 3 →